News | ECMO Systems | September 08, 2015

Extracorporeal Life Support Is “Bridge-to-Life” for Sudden Onset Cardiogenic Shock Patients

Italian study finds dramatic difference in treatment response between acute episodes and those based on chronic deterioration

Maquet, extracorporeal life support, ECLS, cardiogenic shock, bridge-to-life, PLS system

PLS system image courtesy of Maquet

September 8, 2015 — In a new study reported in The Journal of Thoracic and Cardiovascular Surgery, researchers found a dramatic difference in cardiac function recovery with extracorporeal life support (ECLS) after cardiogenic shock depending on the nature of the attack. The results underscore the importance of mechanical circulatory support in helping the patient survive.

Cardiogenic shock is when a patient’s heart is so severely damaged that it is no longer able to pump blood to the organs of the body. When this occurs, mechanical circulatory support may be the only hope for survival. While different options are available, recovery of cardiac function with ECLS differs dramatically depending upon whether the cardiogenic shock results from an acute episode, such as a heart attack, or chronic cardiac deterioration.

“ECLS is a bridge-to-life and should be considered a first-line treatment in primary cardiogenic shock,” explained lead investigator Vincenzo Tarzia, M.D., from the Division of Cardiac Surgery, Department of Cardiac, Thoracic, and Vascular Sciences, Padua University Hospital (Italy). “Therapeutic strategies should be tailored considering the different outcomes with respect to etiology. For those with an acute etiology, short-term ECLS may be the only therapy required.”

Tarzia and colleagues examined the outcomes of 64 patients who received an ECLS device for cardiogenic shock who were refractory to other forms of treatment. Cardiogenic shock had an acute onset in 37 (58 percent) of cases, with 70 percent due to an acute myocardial infarction, 11 percent to myocarditis, 16 percent to a pulmonary embolism and 3 percent to postpartum cardiomyopathy. The investigators compared outcomes in this group to 27 patients who developed cardiogenic shock due to chronic conditions such as dilated cardiomyopathy (74 percent), ischemic cardiomyopathy (19 percent) or congenital myopathy (7 percent).

Investigators found that in the acute group, ECLS was a “bridge-to-recovery” for 18 patients. All of these patients recovered cardiac function and were the only ones in the study to do so, compared with no patients in the chronic group, and this difference was statistically significant. Almost 90 percent of these patients were alive at the one-year follow-up. In the remainder of the acute etiology group, ECLS was used as a bridge-to-transplantation in three patients and a bridge-to-another bridge (such as a ventricular assist device or total, artificial, longer-term support) in nine patients.

The results were very different for the chronic etiology group, in which 14 patients were bridged to a left ventricular assist device and nine received a heart transplant; no patients in this group were “bridged to recovery.”

Thirty-day mortality was higher in the chronic etiology group (26 percent vs. 16 percent). No other differences were noted in mortality during ECLS support, hospital discharge or survival at one-year follow-up.

The investigators also considered how to improve survival for patients placed on ECLS. They found that minimizing the duration of support and maintaining flow rates to about 60 percent of theoretical requirements offered the best chance of survival.

In an accompanying editorial, Vivek Rao, M.D., Ph.D., of Toronto General Hospital, discusses how in recent years ECLS is having a resurgence as a strategy for cardiogenic shock, following initial disappointing experiences with adverse events such as thrombocytopenia, bleeding and thromboembolic complications. “The newer-generation ECLS circuits, as described in this report, have been proven to be more durable, can be rapidly initiated and require less systemic anticoagulation than previous circuits. As such, the clinical outcomes of this therapy have improved considerably,” he said.

The ECLS used in the current study was the PLS system (Maquet Cardiopulmonary AG, Hirrlingen Germany).

The results demonstrate that ECLS outcomes significantly depend upon the condition of the heart and timing of the cardiogenic shock. Rao advised that surgeons should not be discouraged that only 60 percent of the patients survived to hospital discharge. “All of us who have successfully ‘salvaged’ a young 40-year-old patient from near certain death would agree that a 60 percent ‘success rate’ is still a worthwhile endeavor” – especially since about 80 percent of these patients achieved long-term survival.

For more information: www.jtcvsonline.org

Related Content

Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery| September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init